Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4825240 | 0.97 | ALDH1A1 (0.32) | TP53ALDH1A1TSHR | |
| Trifluoroacetic Acid SCHEMBL1890860 | 0.95 | TP53 (0.33) | TP53 | |
| Trifluoroacetic Acid SCHEMBL7065544 | 0.93 | — | — | |
| Trifluoroacetic Acid SCHEMBL16394297 | 0.93 | — | — | |
| Trifluoroacetic Acid SCHEMBL21046091 | 0.91 | ATR (0.32) | — | |
| Trifluoroacetic Acid SCHEMBL16288044 | 0.90 | — | — | |
| Trifluoroacetic Acid SCHEMBL21046071 | 0.89 | DPP8 (0.31) | — | |
| Trifluoroacetic Acid SCHEMBL522873 | 0.88 | — | — | |
| Trifluoroacetic Acid SCHEMBL3190348 | 0.82 | CA12 (0.39) | ALDH1A1 | |
| Dl-Dithiothreitol SCHEMBL28394515 | 0.81 | DPP4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112480211-B | Anti-tumor polypeptide targeting PKM2 protein and application thereof | 中山大学·深圳 | 2022-03-29 | — | — | CN | claimed |
| US-20050176683-A1 | Hexa-/Tetra-hydro-pyrrolo[1,2-a]imidazole-2,5-dione derivatives; solid phase synthesis | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2005-08-11 | — | — | US | claimed |
| WO-2005056523-A2 | METHODOLOGY FOR PREPARING COMBINATORIAL LIBRARIES BASED UPON A BICYCLIC SCAFFOLD | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2005-06-23 | — | — | WO | claimed |
| US-20240190936-A1 | Incretin Analogs and Uses Thereof | ELI LILLY AND COMPANY | 2024-06-13 | — | — | US | disclosed |
| US-20240156973-A1 | OSTEOTROPIC COMPOSITIONS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2024-05-16 | — | — | US | disclosed |
| US-11982674-B2 | Reagents for quantitative mass spectrometry | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4357358-A1 | GLUCAGON ANALOG AND MEDICAL USE THEREOF | Beijing Tuo Jie Biopharmaceutical Co. Ltd. (CN) | 2024-04-24 | — | — | EP | disclosed |
| US-20240124518-A1 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS | AILERON THERAPEUTICS INC (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4353248-A1 | CALCIUM-SENSING RECEPTOR AGONIST COMPOSITION AND APPLICATION THEREOF | Beijing Tuo Jie Biopharmaceutical Co. Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| EP-4048680-B1 | PEPTIDES WITH CELL DAMAGE PROTECTION ACTIVITY AND LIPOSOMIAL FORMULATIONS | I R A ST RICERCHE APPLICATE S P A (IT) | 2024-01-31 | — | — | EP | disclosed |
| EP-4299124-A1 | ANTI-MGLUR2 NANOBODIES FOR USE AS BIOMOLECULE TRANSPORTER | UNIVERSITE DE MONTPELLIER (FR) | 2024-01-03 | — | — | EP | disclosed |
| US-20110160433-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| WO-2011002673-A1 | LEPTIN AGONIST AND METHODS OF USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100210515-A1 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS | AILERON THERAPEUTICS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2010034032-A2 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS | AILERON THERAPEUTIC, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| EP-2053056-A1 | DENDRIMERIC PEPTIDE CONSTRUCT FOR THE PREVENTION OF FOOT-AND-MOUTH DISEASE IN ANIMALS | Instituto Nacional De Investigacion y Tecnologia agraria y Alimentaria (INIA) (ES) | 2009-04-29 | — | — | EP | disclosed |
| US-20090068738-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-03-12 | — | — | US | disclosed |
| US-20050063937-A1 | Multiple-arm peptide compounds, methods of manufacture and use in therapy | INCUBE LABS, LLC | 2005-03-24 | — | — | US | disclosed |
| US-20050008653-A1 | In situ binding of polypeptide to stabilizer; induction apoptosis | MEDICAL RESEARCH COUNCIL | 2005-01-13 | — | — | US | disclosed |
| US-6355673-B1 | BONE DISORDERS; ANTIINFLAMMATORY AGENTS; WOUND HEALING AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008653-A1 | In situ binding of polypeptide to stabilizer; induction apoptosis | BAX, BCL2, BCL2L13 | TP53 32/4885ALDH1A1 4635/4885TSHR 2159/4885 |
| US-20110160433-A1 | BENZYLIC COMPOUND | VIP, NGLY1, FURIN | TP53 3546/4885ALDH1A1 2463/4885TSHR 2705/4885 |
| US-20240124518-A1 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS | VIP, NGLY1, IAPP | TP53 2240/4885ALDH1A1 4861/4885TSHR 1829/4885 |
| US-20100210515-A1 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS | VIP, NGLY1, IAPP | TP53 2240/4885ALDH1A1 4861/4885TSHR 1829/4885 |
| US-20240156973-A1 | OSTEOTROPIC COMPOSITIONS AND USES THEREOF | SOST, BMP2, BMP6 | TP53 1708/4885ALDH1A1 4338/4885TSHR 2814/4885 |
| US-20240190936-A1 | Incretin Analogs and Uses Thereof | GLP1R, GIPR, GCGR | TP53 4672/4885ALDH1A1 3012/4885TSHR 120/4885 |
| US-20090068738-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | PTMS, QPCT, ANPEP | TP53 1354/4885ALDH1A1 3718/4885TSHR 1564/4885 |
| US-20050176683-A1 | Hexa-/Tetra-hydro-pyrrolo[1,2-a]imidazole-2,5-dione derivatives; solid phase synthesis | ADH1A, ADH1C, ADH5 | TP53 1941/4885ALDH1A1 22/4885TSHR 1340/4885 |
| US-11982674-B2 | Reagents for quantitative mass spectrometry | CHAMP1, SRMS, QPCTL | TP53 269/4885ALDH1A1 1505/4885TSHR 3110/4885 |
| US-20050063937-A1 | Multiple-arm peptide compounds, methods of manufacture and use in therapy | ECPAS, FN1, ILK | TP53 2089/4885ALDH1A1 4066/4885TSHR 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.